Dr. Reddy's Laboratories ADR fell 9.69% to $13.19 in New York on Wednesday. (Photo: Envato) Show Quick Read Summary is AI Generated. Newsroom Reviewed

The American Depositary Receipts of Dr. Reddy's Laboratories Ltd. fell 9.69% to $13.19 in New York on Wednesday after the company’s plan to launch a generic version of a popular weight-loss drug in Canada faced a regulatory setback.

The company had received a Notice of Non-Compliance from the Pharmaceutical Drugs Directorate of Canada, the company said in an exchange filing.

The notice pertains to Dr. Reddy’s Abbreviated New Drug Submission for Semaglutide Injection—a drug widely used for weight management and diabetes control.

According to the company, the NON seeks additional information and clarifications on specific aspects of

See Full Page